GSK to Acquire Nuvalent for $10.6 Billion in Major Lung Cancer Pipeline Expansion
Key Insights
GSK has agreed to acquire Boston-based oncology firm Nuvalent for $10.6 billion, marking its largest deal in over a decade.
The acquisition includes two late-stage lung cancer (search) candidates, zidesamtinib and neladalkib, both with FDA breakthrough therapy and orphan drug designations.
Subject to FDA approval, the drugs are expected to launch in 2026 with multi-blockbuster potential, contributing to revenue growth from 2027.
GSK has agreed to acquire Boston, Massachusetts-based oncology-focused biopharmaceutical company Nuvalent for $10.6 billion, the London-based pharmaceutical firm's largest transaction in over a decade. The deal, announced ahead of Tuesday's London market open, represents a 40% premium to Nuvalent's last closing price, with GSK set to commence a tender offer to acquire all outstanding shares at $124 per share in cash within 10 business days. Net of cash acquired, GSK's aggregate investment is estimated at $9.4 billion.
The acquisition is described by GSK as "consistent" with its strategy of "acquiring assets that have validated targets and meaningfully address efficacy and/or tolerability limitations of existing standard-of-care therapies."
Pipeline Assets and Regulatory Status
The deal brings three lung cancer (search) products into GSK's portfolio, headlined by two late-stage, potential best-in-class drug candidates: zidesamtinib and neladalkib. Both compounds have received US Food & Drug Administration breakthrough therapy and orphan drug designations, underscoring their potential to address significant unmet needs in lung cancer treatment.
Subject to FDA approval, the drugs are expected to launch in 2026 with what GSK describes as "multi-blockbuster potential."
Strategic Rationale and Financial Impact
GSK Chief Executive Officer Luke Miels emphasized the strategic value of the transaction, stating: "The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer (search) for rapid expansion with Ris-Rez (search), our B7-H3 targeted ADC in phase III clinical development."
The company confirmed there is no change to GSK's 2026 full-year guidance range of 7-9% core operating profit and core earnings per share growth. The acquisition is expected to contribute to revenue growth beginning in 2027.
The transaction marks GSK's most significant M&A move since a $20 billion deal in 2014, signaling a renewed commitment to strengthening its oncology portfolio through targeted acquisitions of clinically validated assets.